Carisma Therapeutics, Inc. (CARM) Stock Chart - Revenue & Earnings | Quarter Chart
Revenue by Product
Revenue by Geography
Revenue, Gross Profit, Operating and Net Income
Margin (%)
Operating Expenses
EBITDA
EPS
Revenue Variation (%)
Income Variation (%)
Revenue YoY Variation (%)
Income YoY Variation (%)
Price-to-Earning Ratio
Income Breakdown
Per Share Metrics
Expense Ratios
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt Ratio
Current Ratio
Quick Ratio
Cash & Equivalents
Total Assets
Total Liabilities
Shareholders Equity
Asset Composition
Debt Structure
Carisma Therapeutics, Inc. (CARM) quarterly earnings & revenue
Carisma Therapeutics, Inc. (CARM) reported revenue of $45.25M for Q3 2025, up 1236.8% year-over-year, with net income of $44.72M and diluted EPS of $1.07.
Over the last four reported quarters, Carisma Therapeutics, Inc. generated $52.63M in revenue and $8.04M in net income.
Carisma Therapeutics, Inc.'s next earnings report is scheduled for May 28, 2026 after market close; analysts estimate EPS of $-0.15.
Carisma Therapeutics, Inc. quarterly results
| Fiscal quarter | Revenue | Revenue YoY | Net income | EPS (diluted) |
|---|---|---|---|---|
| Q3 2025 | $45.25M | +1236.8% | $44.72M | $1.07 |
| Q2 2025 | — | — | $-9.77M | $-0.23 |
| Q1 2025 | $3.73M | +9.8% | $-9.27M | $-0.22 |
| Q4 2024 | $3.65M | -14.8% | $-17.64M | $-0.42 |
| Q3 2024 | $3.38M | -11.5% | $-12.70M | $-0.31 |
| Q2 2024 | $9.20M | +158.3% | $-11.16M | $-0.27 |
| Q1 2024 | $3.40M | +4.7% | $-18.98M | $-0.46 |
| Q4 2023 | $4.29M | +15.0% | $-20.96M | $-0.52 |
Carisma Therapeutics, Inc. (CARM) — frequently asked questions
When does Carisma Therapeutics, Inc. (CARM) report earnings next?
Carisma Therapeutics, Inc. is expected to report earnings on May 28, 2026 after market close. Analysts estimate EPS of $-0.15.
What was CARM's revenue last quarter?
Carisma Therapeutics, Inc. reported revenue of $45.25M in Q3 2025, up 1236.8% from the same quarter a year earlier.
What was CARM's EPS last quarter?
Carisma Therapeutics, Inc. reported diluted EPS of $1.07 in Q3 2025.
Is Carisma Therapeutics, Inc. profitable?
Carisma Therapeutics, Inc. is currently profitable, with $8.04M in net income over the last four reported quarters.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)